Long-Term Exposure to Low-Dose Prednisone With Abiraterone Acetate for mCRPC
Leonard Gomella, MD, professor, Jefferson University, physician, chair, Department of Urology, director, Kimmel Cancer Center Network, discusses results from a study that assessed the corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer (mCRPC).
Leonard Gomella, MD, professor, Jefferson University, physician, chair, Department of Urology, director, Kimmel Cancer Center Network, discusses results from a study that assessed the corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer (mCRPC).
<<<
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
